Esophagus Disorders
Also known as: Esophagus, Esophageal, Esophagitis, Esophageal dysphagia, Stenosis
Methodology & AI Transparency ⓘ
Esophagus Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are esophagus disorders? Esophagus disorders are problems with how your esophagus works.
- 2 Real-world patient consensus: Synonyms for Esophagus Disorders (K20.90): Esophagus, Esophageal, Esophagitis (GERD & Stomach).
- 3 Typical cash cost range: Clinicians assessing Esophagus Disorders focus on impaired esophageal peristaltic in Esophagus Disorders (K20.90: clearance) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Esophagus Disorders: maintaining Hemoglobin & Serum in Esophagus Disorders (K20.90: Ferritin) within Ferritin > 50 ng/mL (no occult loss) (K20.90).
Ask our AI Specialists anything about Esophagus Disorders
What Is Esophagus Disorders?
What are esophagus disorders? Esophagus disorders are problems with how your esophagus works. The esophagus is the tube that carries food from your mouth to your stomach. You usually don't notice it unless you swallow something too big, hot, or cold. You might also notice it if something is wrong. When that happens, you might feel pain or have trouble swallowing (dysphagia). What causes esophagus disorders? The cause depends on the type of disorder. Some run in families. Others are linked to allergic reactions to food or substances in your environment. Sometimes, the cause is unknown.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Esophagus Disorders (K20.90) features impaired esophageal peristaltic in Esophagus Disorders (K20.90: clearance). Cross-referenced with NIH MeSH (Esophageal Diseases), therapeutic stabilization in gerd & stomach is verified against Serum Vitamin B12 in Esophagus Disorders (K20.90: & Magnesium (chronic).
Common Symptoms & Clinical Signs
- • Are overweight or have obesity
- • Take certain medicines
- • Presentation of Esophagus Disorders (K20.90): post-meal retrosternal heartburn in Esophagus Disorders (K20.90: or sour acid)
- • Secondary Esophagus Disorders clinical sign: epigastric burning, early in Esophagus Disorders (K20.90: satiety, or upper-abdominal)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Esophagus Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K20.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Esophagus Disorders (K20.90: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (K20.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Esophagus Disorders (K20.90: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K20.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Esophagus Disorders (K20.90: Antigen or Urea) | Negative (K20.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Esophagus Disorders
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dyclonine Hydrochloride Dyclopro, Sucrets Sore Throat Wild Cherry • RxCUI 1048281 | FDA Prescription Therapeutic Agent | 81% | $0.2800 | $ 19.84 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Esophagus Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Interim analysis of patient-reported outcome compliance and dosimetry in a phase Compliance was lower than anticipated and interventions to maintain study power are needed. Acta oncologica (Stockholm, Sweden) • 2023-11-15 • Phase III Randomized Trial | N = 100 | 82/100 | PMID 37647380 ↗ |
| Can This Approach Help? Inside the Latest Research on Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A Esophagus-sparing VMAT/IMRT did not reduce peak dysphagia in the intention-to-treat analysis but showed a significant benefit in the per-protocol analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2025-06-15 • Phase III Randomized Trial | N = 188 | 82/100 | PMID 40324910 ↗ |
Esophagus Disorders Patient Community & “People Like Me” Threads
Filter Esophagus Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.